Gout is an inflammatory musculoskeletal disorder with a prevalence of 1.6-6.8% in Australia. Gout is characterised by acute attacks of severe joint pain secondary to raised serum concentrations of uric acid and joint deposits of monosodium urate crystals. Recurrent attacks can affect quality of life and lead to irreversible joint damage. The prevalence of gout is increased in older people, and agerelated renal impairment, altered drug distribution and increased prevalence of comorbidities have significant consequences for safe and effective gout pharmacotherapy. For treatment of acute attacks in older people, dose reduction of colchicine may be needed due to renal impairment, and potential drug interactions require consideration. Use of non-steroidal anti-inflammatory drugs is limited by peptic ulceration, ischaemic heart disease, hypertension and renal impairment. Short courses of oral glucocorticoids may be preferable. For long-term urate-lowering therapy, allopurinol, probenecid and febuxostat are available in Australia. Lower starting doses of allopurinol are recommended in patients with renal impairment, but dose escalation to achieve target urate should follow. Concerns regarding increased cardiovascular risk with febuxostat are relevant to older patients. Despite the availability of effective therapy, gout remains undertreated, with maintenance of urate-lowering therapy a major challenge. Education of patients and health professionals is essential to improve adherence to therapy.
INTRODUCTION
Gout is an inflammatory musculoskeletal disorder. Negative connotations about gout abound, but the relationship with excessive alcohol intake is the most pernicious. Although there is some truth in the association, it is not a universal feature of those with this condition. The major effect of gout on those who suffer it is well reflected in Lady Mary Wortley Montagu's declaration in the 18 th century, 'People wish their enemies dead -but I do not; I say give them the gout'. 1 Gout has been overlooked by health policy makers, clinicians and society generally in favour of conditions where 'lifestyle' choices are not considered to have contributed -various cancers, for example.
WHY FOCUS ON GOUT IN OLDER PEOPLE?
The incidence and prevalence of gout increases with age. So do comorbidities, notably those that are part of the metabolic syndrome, namely Type 2 diabetes, hypertension and dyslipidaemia. 2, 3 Renal function declines with age, which contributes to the increasing incidence of gout and has significant consequences for safe and effective gout pharmacotherapy. Adverse drug reactions increase with age because of declining efficiency of clearance mechanisms, changes in drug distribution due to the relative loss of muscle and increase in fat, and generally increased end-organ sensitivity. 4, 5 The multiple comorbidities common in patients with gout usually mean multiple medications, increasing the risk of drugdrug interactions and the hazards that accrue from polypharmacy. 6 The burden of musculoskeletal disorders in the older population, including gout, is profound. This is a major contributor not only to substantial decrements in quality of life and large financial cost, but also reduced ability to exercise and control weight, thereby exacerbating the toll from the metabolic syndrome. 7 
WHY PHARMACISTS SHOULD BE INTERESTED IN GOUT
Gout is most commonly observed in the community setting. Although attacks often happen in hospitals following surgery or other stressful presentations, community pharmacists are often the first port of call for people living with gout. Pharmacists can play an important role in the ongoing management of people with gout, by supporting adherence to non-pharmacological and pharmacological strategies to reduce the risk of acute attacks and avoid preventable medication-related harm. Although pharmacists have expressed an interest in this role, 8 to date the contribution of community pharmacy to improving outcomes for people with gout has been reported to be small. 9 
ABOUT GOUT
Gout is the most common inflammatory arthritis in men. 10 The prevalence of gout in Australia is 1.6% of patients attending general practices, and this is increasing, reflecting a world-wide phenomenon in both developed and developing nations. [11] [12] [13] In the 2007-08
National Health Survey, 4.7% of working age Australians self-reported gout. 14 In a 2015 South Australian population survey, gout prevalence was reported to be 6.8%. 15 In Indigenous Australians, the prevalence of gout is 3.8% overall and 7% in men according to a 2002 survey undertaken in north Queensland, 16 but there is uncertainty about these prevalence rates. 17 The condition is much more common in men than women, with 20% of men in Sydney (NSW, Australia) over the age of 70 years self-reporting gout when surveyed between 2005 and 2007. 18 The condition becomes more prevalent in women past the menopause, approaching rates seen in men.
Attacks of gout are extremely painful and most commonly occur in the base of the great toe, although any joint is susceptible. An acute attack is a self-limiting condition that, apart from being very painful, substantially intrudes on the sufferer's life. If attacks are recurrent, commonly due to inadequate management, quality of life is considerably reduced, a fact that is generally underappreciated. 19, 20 Gout occurs in people with raised serum concentrations and body loads of urate, the circulating ionised form of uric acid. This condition is known as hyperuricaemia. The definition of hyperuricaemia is contentious, with different reference ranges for urate concentrations quoted on pathology reports from different sources. Urate concentrations in the population are not normally distributed, but are skewed in the direction of higher concentrations. 21 Urate concentrations tend to increase with age, renal impairment and after the menopause, 22 the latter likely due to the loss of oestrogen, which enhances urate clearance via the kidneys. The upper limit of a commonly reported 'normal range' for urate is 0.42 mmol/L. This was likely chosen because it is also the solubility point for urate, above which urate can precipitate to form monosodium urate crystals. 23 However, many individuals have higher urate concentrations and never suffer with gout, a condition known as 'asymptomatic hyperuricaemia'. This is not an indication for urate-lowering therapy (ULT). Conversely, individuals with urate concentrations <0.42 mmol/L can present with gout. We now know that the propensity to experience gout attacks is affected by an individual's innate immunity and ability to trigger the formation of the 'inflammasome' in response to crystals of urate forming in joints. 24, 25 One complication in evaluating suspected gout is that the serum urate concentration drops during an acute attack, which may divert the clinician from consideration of the diagnosis. A definitive diagnosis is made by demonstrating needle-shaped, negatively birefringent crystals in aspirated joint fluid. Unsurprisingly, the higher an individual's urate concentration, the more likely a gout attack is to occur. If urate concentrations are maintained below 0.36 mmol/L, gout attacks will cease and accumulated deposits of urate crystals in the joints, subcutaneous tissue and organs such as the kidney will dissipate, the latter even faster if urate concentrations are maintained below 0.3 mmol/ L. 26, 27 Urate is the end-product of the metabolism of purines that are released when cells die and nucleic acids from DNA and RNA are released. Rarely, the metabolic pathway forming urate is overactive due to genetic variants in some of the enzymes involved, leading to hyperuricaemia. More commonly, the kidneys of people with hyperuricaemia are less efficient at clearing urate from the blood via renal tubular transport systems than those without hyperuricaemia, resulting in elevated urate concentrations. This reduced renal clearance has been attributed to genetic variation in the drug transporters responsible for movement of urate across the renal tubule. 28, 29 Renal impairment also contributes to raised urate. Recurrent acute attacks, apart from being distressing and disruptive, signal possible joint and organ damage, especially kidney damage. This is the signal for the sufferer and clinician to contemplate pharmacotherapy to prevent recurrence and damage from continued deposition of crystals in joints and organs. Effective therapies are available to reduce urate plasma concentration to levels at which recurrent attacks will settle (<0.36 mmol/ L) and excess deposits of monosodium urate will dissipate (<0.30 mmol/L recommended).
Of all the rheumatic disorders, gout is the only one where a patient can be guaranteed that there will be no further attacks of gout so long as their plasma urate is controlled by taking their ULT. Yet, the prevalence of this condition continues to increase. There are two explanations: (1) most importantly, adherence to therapy is essential to guarantee elimination of attacks; and (2) the dose of ULT needs to be sufficient to achieve the aforementioned plasma urate concentrations.
ABOUT GOUT MANAGEMENT: PHARMACOTHERAPY AND ISSUES IN OLDER PEOPLE
Attention to lifestyle, including diet and exercise, and attending to comorbidities and risk factors for accelerated cardiovascular disorders is a critical component of the management and education of people with gout, although most of the benefit from these measures derives from reduction of cardiovascular risk. [30] [31] [32] [33] The focus upon pharmacotherapy in this paper should not be construed as undervaluing the contribution of nonpharmacological interventions to the long-term health of people with gout.
Acute Gout
Acute attacks of gout can be treated with colchicine, non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids. Some people use adrenocorticotrophin (ACTH) injections, but the advantage of this approach relative to glucocorticosteroids is not established. 34 Rarely, colchicine, NSAIDs and oral and injectable glucocorticosteroids are contraindicated and, in the absence of infection, rheumatologists may prescribe parenterally administered drugs that block the cytokine interleukin-1, such as canakinumab and anakinra. 33 Colchicine A revision to the long-held guidance to dose colchicine until abdominal pain and diarrhoea occur has been an important advance. In an acute attack of gout, the correct regimen is to take two colchicine 0.5-mg tablets (total dose 1 mg), followed by one 0.5-mg tablet 1 h later and then withhold the drug for at least 24 h. This approach is effective and substantially safer. 35 Because the drug is partially cleared by the kidneys (~40-60%), the dose should be reduced if the patient's creatinine clearance is reduced (e.g. <30 mL/min). 36, 37 Colchicine is also metabolised in the liver by cytochrome P450 3A4/5 and subject to transport from the systemic circulation to the gut via P-glycoprotein. These clearance mechanisms put patients on colchicine at risk of serious drug interactions, notably by drugs that inhibit cytochrome P450 3A4/5 and P-glycoprotein, such as clarithromycin and diltiazem. 38 Safe storage of colchicine is important because it is lethal in overdose because it inhibits cell division by inhibiting microtubule assembly during cell replication. 28 Unfortunately, the drug is without an antidote. Children are at serious risk if they can access this drug.
Non-steroidal Anti-inflammatory Drugs
There is no good reason to pick one NSAID over another. Although indomethacin has a historical position as the NSAID of choice, this is no longer appropriate because it also has more of the adverse effects shared by all NSAIDs, including gastrointestinal intolerance with indigestion and ulceration, exacerbation of hypertension, cardiac failure, renal impairment and the risk of thrombosis, particularly myocardial infarction. Ibuprofen, meloxicam or naproxen are reasonable choices, the key being to limit duration of therapy to the 5-7 days of an attack and to protect the upper gastrointestinal tract with a proton pump inhibitor. [39] [40] [41] Older patients with past peptic ulceration, ischaemic heart disease, hypertension or renal impairment are at greater risk for exacerbations of these conditions, so avoidance of NSAIDs in this age group is preferred.
cardiac failure are hazards, but short exposures can generally be managed. There is also the option of injecting a synthetic glucocorticoid into affected joint(s), which is highly effective but more realistic for larger joints such as the knee.
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Recurrent and Persistent Gout
Urate-Lowering Therapy
The major challenge for ULT is maintaining adherence and persistence with therapy. Rates of persisting with ULT are low, ranging from 40% to 70%, with most studies reporting rates below 50% at 1 year. [42] [43] [44] Older people are more likely to be taking multiple medicines for comorbid health conditions and, as such, may have more problems with adherence. An important disincentive to maintaining adherence is the occurrence of acute attacks of gout in the first 6 months after commencing ULT. This phenomenon is more common if the serum urate concentration is lowered rapidly. Not surprisingly, patients not expecting this after commencing a therapy to prevent gout are likely to lose confidence in ULT. The likelihood of acute attacks during the induction of ULT has led to the mantra 'start low, go slow' to describe the approach to establishing ULT over the first 6 months, to reduce the risk of acute attacks. 45 The other strategy is to coprescribe prophylactic therapy against acute attacks for these initial 6 months. 46 Any of the three options described earlier (colchicine, NSAIDs or corticosteroids) can be used, but colchicine has emerged as the most appropriate, especially for older patients. NSAIDs or prednisolone therapy for 6 months in this age group, especially with cardiovascular comorbidities, is inadvisable. Colchicine dosing should be reduced from a standard 0.5 mg twice a day to once a day in those with renal impairment (e.g. creatinine clearance <30 mL/min). Dosing also needs to be reduced if loose bowels are an issue. It is important that patients are educated to recognise the adverse effects of colchicine so that early dose adjustment or discontinuation occurs.
Allopurinol
Allopurinol inhibits urate synthesis by xanthine oxidoreductase, also known as xanthine oxidase. 23 There has been an important shift in how we use this highly effective medicine. Concern regarding Stevens-Johnson syndrome (SJS), a severe cutaneous and mucosal consequence of allopurinol hypersensitivity, and the now contested relationship to dose and renal impairment, 47 led to dosing advice that achieved neither enhanced safety nor control of gout. 48 The active metabolite of allopurinol, oxypurinol, is cleared exclusively by the kidneys and is retained in renal impairment. 23 Hence, guidelines had recommended dose reduction in keeping with renal function. 28 As a result, older people, with their higher rates of renal impairment, were systematically underdosed because of fear of allopurinol hypersensitivity such that the target urate concentration was not commonly achieved and gout was often uncontrolled. The advice to limit the dose in people with renal impairment has been superseded, and most contemporary guidelines recommend dose increases until urate target concentrations are reached; this often means that allopurinol doses exceed 300 mg/day. 27 A further important insight has been the revelation that the daily dose of allopurinol, or indeed any ULT, required to reach target concentrations correlates with the pretreatment serum urate concentration. 49, 50 Examination of plasma concentrations of oxypurinol has indicated that they are not better correlated with urate concentrations than dose, such that measuring oxypurinol can be reserved for cases where a lack of response is not understood, often non-adherence being suspected. 50 Regardless of the approach, the risk of allopurinol hypersensitivity remains. However, it is known to be much more likely to occur in patients who have one or two HLA-B*58:01 antigens indicating the autoimmune pathogenesis of this devastating adverse reaction. 51 It is recommended that this human leucocyte antigen (HLA), which has a prevalence of approximately 15% in Han Chinese, a little less in Koreans and Thai people but much less in Caucasians, is tested for in higher-risk patients if allopurinol is being considered, the test being 100% specific for SJS, although not very sensitive.
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Guidelines now recommend a starting dose of allopurinol based on renal function, with the dose then increased at 2-to 5-weekly intervals until the target urate serum concentration is reached. 55 The manufacturer's product information (https://www.mimsonline.com.au.acs.hcn.com.au/ Search/FullPI.aspx?ModuleName=Product%20Info&searc hKeyword=allopurinol&PreviousPage=~/Search/QuickSea rch.aspx&SearchType=&ID=124000001_2) notes that the upper limit for dosing is 900 mg/day, so there is plenty of room to move.
Uricosuric Medicines: Probenecid, Lesinurad, Verinurad and Benzbromarone
Members of this class of medicines inhibit the uptake of urate from the proximal renal tubule by inhibiting the uric acid transporter URAT1 on the renal tubule membrane. 56 Experience indicates that the efficacy of uricosuric medications is not substantively different from that of allopurinol if doses of allopurinol are adjusted according to serum urate, but well-conducted head-tohead studies are lacking. Moderate renal function at least is required for efficacy, but there is variation across the class in this regard. A hazard with commencing this class of ULT, in addition to the risk of precipitating an attack of gout, is precipitation of urate in the renal tubules leading to acute obstructive uropathy. This is countered by maintaining hydration through this risk period and following the 'start low, go slow' dosing maxim. Combinations of allopurinol and uricosuric medicines are rational and highly effective if doses of either alone are insufficient to reach target urate concentrations. [57] [58] [59] [60] Probenecid is available in Australia; lesinurad is registered in Europe and the US, but not Australia; 61 verinurad, a molecule related to lesinurad, is in an advanced stage of clinical development and is claimed to have a lower renal impairment signal than its forebear and is likely to reach the market soon; 62 and benzbromarone was withdrawn from the Australian market because of serious hepatotoxicity in a small number of patients and is now only accessible via the Special Access Scheme, reserved for patients where other ULT options are not tolerated. 63 Benzbromarone is a potent uricosuric and remains active at lower creatinine clearance levels than probenecid.
Febuxostat
Febuxostat is an alternative xanthine oxidoreductase inhibitor available on the Australian Pharmaceutical Benefits Scheme as an Authority Required medicine for chronic or tophaceous gout in patients with a medical contraindication to allopurinol, a documented history of allopurinol hypersensitivity syndrome or intolerance of allopurinol (http://www.pbs.gov.au/medicine/item/10445R). Febuxostat is a useful addition to the armamentarium for ULT, but 'leakage' beyond these criteria is likely, and the development of this and other ULT medicines at great expense to individuals and the community has been critiqued. 64 There were concerns at registration that there was a cardiovascular risk associated with febuxostat, which has been confirmed recently in comparison with allopurinol. 65 This is of great relevance to older patients with cardiovascular comorbidities and risk factors, leading some commentators to opine that this drug should not be considered as a first-line drug. 66 
PUBLIC HEALTH OPPORTUNITIES
Gout is the 'Cinderella' of musculoskeletal conditions; prevalent, impactful and eminently treatable with a close to 100% success rate, but the condition is sadly overlooked. The barriers to effective treatment on a national scale are clear. 67 Improved rates of treatment persistence, based upon education of patients and health professionals, including pharmacists, are needed. Innovative and cost-effective public health interventions are also needed. As a current example in Australia, the use of a mobile app to educate and receive individualised feedback regarding serum urate concentrations is undergoing testing in a double-blind cluster-randomised controlled trial in primary care. 68 Indigenous Australians are at risk for gout and its consequences, and more recent recognition of this propensity is a step towards culturally-appropriate programs to improve the lives of those afflicted. 12 
WHAT'S NEW IN GOUT?
The move towards 'treat to target' serum urate concentrations has emerged in the past decade and has shown that most people can achieve target concentrations by allopurinol dose adjustments. The concerns about this practice in people with renal impairment have largely been allayed, although more evidence for safety is needed. The challenge is to implement this change across primary care. In this sector, changing dosing practice is difficult because restriction of maximum doses had previously been strongly promoted.
The best methods for establishing effective ULT, with the express purpose of building confidence that the condition can be controlled without increased risk of serious toxicity, remains a work in progress. Most authorities recommend starting with low doses of ULT according to renal function, then increasing the dose in small increments until the target urate concentration is achieved, with coverage for acute attacks. The optimal duration of this cotherapy is not yet established, but most guidelines suggest 6 months. This could vary depending on the duration of gout, the baseline urate and the presence of gouty tophi, the latter being associated with a longer period of risk. 29 Recent work supports early initiation of ULT, even during an acute attack, and, importantly, not ceasing ULT if an attack occurs.
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POTENTIAL FOR PHARMACY CONTRIBUTION
Persistence with ULT is the greatest challenge in the successful management of gout. Because pharmacists interact regularly with people with gout who are taking ULT and prophylactic treatment for acute attacks of gout, there is an opportunity to monitor and improve persistence. Community pharmacists, as trusted advisers to their clients, can also identify patients who are having acute gout attacks. These patients may not have started ULT and this effective option can be canvassed. During
Journal of Pharmacy Practice and Research (2019) 49, 90-97 © 2019 The Society of Hospital Pharmacists of Australia the initiation of ULT, patients experiencing acute attacks can be reassured that these will cease when serum urate concentrations remain below 0.36 mmol/L for 6 months. In addition, these patients can be advised regarding the benefits of continuing to take ULT even if an acute attack occurs in this 6-month 'establishment phase'. An increase in the dose of a patient's prophylactic colchicine may be appropriate if not exceeding 0.5 mg twice a day, and referral back to the patient's general practitioner (GP) could be recommended accordingly. Finally, when people present with features of a gout attack, for example very painful acute pain, most commonly at the base of their great toe, this diagnostic suggestion can be made and referral to their GP recommended. Innovative collaborative public health programmes involving community pharmacists, district nurses, GPs and specialists are being explored. Point-of-care testing for urate and allopurinol dose adjustments undertaken by community pharmacists has demonstrated promising results in the effort to reduce the burden of gout among the Mãori peoples of New Zealand. 71 
CONCLUSION
The effectiveness of gout management in the community is poor, resulting in impaired quality of life for sufferers.
There is widespread lack of understanding about the condition and how to manage it effectively. There is stigma associated with the label, with some even suggesting a name change to 'crystal arthritis'. There are challenges in commencing ULT that are hard to convey to people who have gout, and these challenges are not well understood by prescribers. Comorbidities, polypharmacy, organ function decline, drug interactions and drug-disease interactions all add to the complexity and challenges of dealing with gout in the older person. Given the centrality of pharmacotherapy to this condition, the opportunity for pharmacists to make a major contribution to improving outcomes is obvious.
